Many of the best multi-baggers such as EUA, ARB and GGP started off with the same gaps through resistance as the technical buy signal.
Charting Multibaggers, Characteristics of the best-performing stocks, 17th January 2020
Charting Multibaggers, Bulletin Board Heroes, Sunday 10th January 2020
Zak Mir highlights some of the most followed stocks on the small-cap and gives an overview in this video charting update on why they joined that special group of “Multibaggers”
Avacta Group PLC (AVCT.L) License Agreement with POINT Biopharma Inc.
License to utilise Avacta’s pre|CISIONTM FAP sensitive activation platform for radiopharmaceuticals
Share Talk Bulletin Board Heroes, Tuesday, 5th January 2021
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
Avacta Group PLC (AVCT.L) SARS-CoV-2 Rapid Antigen Test Update
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, is pleased to announce significant progress in the development
Weekend Special, Bulletin Board Heroes, Sunday 15th November 2020
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
Pharma Special, Bulletin Board Heroes, Tuesday 10th November 2020
Zak Mir highlights some of the most followed pharmaceutical stocks on the small-cap London market and gives an overview in this video charting update.
Pharma Special, Bulletin Board Heroes, Tuesday 27th October 2020
Zak Mir highlights some of the most followed pharmaceutical stocks on the small-cap London market and gives an overview in this video charting update.
Share Talk Bulletin Board Heroes, Monday 5th October 2020
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this video charting update.
TPI provides its latest research note on Avacta Group Plc (AVCT.L).
Avacta released its unaudited interim results for the six-month period ended 30 June 2020 on Monday. They detailed a period of significant advancement for the Group despite the restrictions placed upon it
Avacta Group plc (AVCT.L) Launch of SARS-CoV-2 BAMSTM Research Test
Affimer-based research assay launched alongside performance data published by Bruker
